A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

Sabino De Placido, Michele De Laurentiis, Mario De Lena, Vito Lorusso, Angelo Paradiso, Modesto D'Aprile, Giorgio Pistillucci, Antonio Farris, Maria Giuseppina Sarobba, Salvatore Palazzo, Luigi Manzione, Vincenzo Adamo, Sergio Palmeri, Francesco Ferraù, Rossella Lauria, Clorindo Pagliarulo, Giuseppe Petrella, Gennaro Limite, Raffaele Costanzo, Angelo Raffaele Bianco

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A × CMF or arms a + c vs b + d) and (2) the effect of adding GT after chemotherapy (arms a + b vs c + d). At a median follow-up of 72 months, A → CMF as compared to CMF significantly improved disease-free survival (DFS) with a multivariate hazard ratio (HR) = 0.740 (95% confidence interval (CI): 0.556-0.986; P = 0.040) and produced a nonsignificant improvement of overall survival (OS) (HR = 0.764; 95% CI: 0.489-1.193). The addition of GT after chemotherapy significantly improved DFS (HR = 0.74; 95% CI: 0.555-0.987; P = 0.040), with a nonsignificant improvement of OS (HR = 0.84; 95% CI: 0.54-1.32). A → CMF is superior to CMF. Adding GT after chemotherapy is beneficial for premenopausal node-positive patients.

Original languageEnglish
Pages (from-to)467-474
Number of pages8
JournalBritish Journal of Cancer
Volume92
Issue number3
DOIs
Publication statusPublished - Feb 14 2005

Fingerprint

Goserelin
Tamoxifen
Doxorubicin
Breast Neoplasms
Drug Therapy
Confidence Intervals
Disease-Free Survival
Therapeutics
Survival
Methotrexate
Fluorouracil
Cyclophosphamide
Research Design

Keywords

  • Adjuvant therapy
  • Anthracyclines
  • Breast cancer
  • Chemoendocrine treatment
  • Premenopausal

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. / De Placido, Sabino; De Laurentiis, Michele; De Lena, Mario; Lorusso, Vito; Paradiso, Angelo; D'Aprile, Modesto; Pistillucci, Giorgio; Farris, Antonio; Sarobba, Maria Giuseppina; Palazzo, Salvatore; Manzione, Luigi; Adamo, Vincenzo; Palmeri, Sergio; Ferraù, Francesco; Lauria, Rossella; Pagliarulo, Clorindo; Petrella, Giuseppe; Limite, Gennaro; Costanzo, Raffaele; Bianco, Angelo Raffaele.

In: British Journal of Cancer, Vol. 92, No. 3, 14.02.2005, p. 467-474.

Research output: Contribution to journalArticle

De Placido, S, De Laurentiis, M, De Lena, M, Lorusso, V, Paradiso, A, D'Aprile, M, Pistillucci, G, Farris, A, Sarobba, MG, Palazzo, S, Manzione, L, Adamo, V, Palmeri, S, Ferraù, F, Lauria, R, Pagliarulo, C, Petrella, G, Limite, G, Costanzo, R & Bianco, AR 2005, 'A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer', British Journal of Cancer, vol. 92, no. 3, pp. 467-474. https://doi.org/10.1038/sj.bjc.6602355
De Placido, Sabino ; De Laurentiis, Michele ; De Lena, Mario ; Lorusso, Vito ; Paradiso, Angelo ; D'Aprile, Modesto ; Pistillucci, Giorgio ; Farris, Antonio ; Sarobba, Maria Giuseppina ; Palazzo, Salvatore ; Manzione, Luigi ; Adamo, Vincenzo ; Palmeri, Sergio ; Ferraù, Francesco ; Lauria, Rossella ; Pagliarulo, Clorindo ; Petrella, Giuseppe ; Limite, Gennaro ; Costanzo, Raffaele ; Bianco, Angelo Raffaele. / A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. In: British Journal of Cancer. 2005 ; Vol. 92, No. 3. pp. 467-474.
@article{0c6e6c82a35a48dabd9881bde29ac4d7,
title = "A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer",
abstract = "The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A × CMF or arms a + c vs b + d) and (2) the effect of adding GT after chemotherapy (arms a + b vs c + d). At a median follow-up of 72 months, A → CMF as compared to CMF significantly improved disease-free survival (DFS) with a multivariate hazard ratio (HR) = 0.740 (95{\%} confidence interval (CI): 0.556-0.986; P = 0.040) and produced a nonsignificant improvement of overall survival (OS) (HR = 0.764; 95{\%} CI: 0.489-1.193). The addition of GT after chemotherapy significantly improved DFS (HR = 0.74; 95{\%} CI: 0.555-0.987; P = 0.040), with a nonsignificant improvement of OS (HR = 0.84; 95{\%} CI: 0.54-1.32). A → CMF is superior to CMF. Adding GT after chemotherapy is beneficial for premenopausal node-positive patients.",
keywords = "Adjuvant therapy, Anthracyclines, Breast cancer, Chemoendocrine treatment, Premenopausal",
author = "{De Placido}, Sabino and {De Laurentiis}, Michele and {De Lena}, Mario and Vito Lorusso and Angelo Paradiso and Modesto D'Aprile and Giorgio Pistillucci and Antonio Farris and Sarobba, {Maria Giuseppina} and Salvatore Palazzo and Luigi Manzione and Vincenzo Adamo and Sergio Palmeri and Francesco Ferra{\`u} and Rossella Lauria and Clorindo Pagliarulo and Giuseppe Petrella and Gennaro Limite and Raffaele Costanzo and Bianco, {Angelo Raffaele}",
year = "2005",
month = "2",
day = "14",
doi = "10.1038/sj.bjc.6602355",
language = "English",
volume = "92",
pages = "467--474",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

AU - De Placido, Sabino

AU - De Laurentiis, Michele

AU - De Lena, Mario

AU - Lorusso, Vito

AU - Paradiso, Angelo

AU - D'Aprile, Modesto

AU - Pistillucci, Giorgio

AU - Farris, Antonio

AU - Sarobba, Maria Giuseppina

AU - Palazzo, Salvatore

AU - Manzione, Luigi

AU - Adamo, Vincenzo

AU - Palmeri, Sergio

AU - Ferraù, Francesco

AU - Lauria, Rossella

AU - Pagliarulo, Clorindo

AU - Petrella, Giuseppe

AU - Limite, Gennaro

AU - Costanzo, Raffaele

AU - Bianco, Angelo Raffaele

PY - 2005/2/14

Y1 - 2005/2/14

N2 - The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A × CMF or arms a + c vs b + d) and (2) the effect of adding GT after chemotherapy (arms a + b vs c + d). At a median follow-up of 72 months, A → CMF as compared to CMF significantly improved disease-free survival (DFS) with a multivariate hazard ratio (HR) = 0.740 (95% confidence interval (CI): 0.556-0.986; P = 0.040) and produced a nonsignificant improvement of overall survival (OS) (HR = 0.764; 95% CI: 0.489-1.193). The addition of GT after chemotherapy significantly improved DFS (HR = 0.74; 95% CI: 0.555-0.987; P = 0.040), with a nonsignificant improvement of OS (HR = 0.84; 95% CI: 0.54-1.32). A → CMF is superior to CMF. Adding GT after chemotherapy is beneficial for premenopausal node-positive patients.

AB - The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A × CMF or arms a + c vs b + d) and (2) the effect of adding GT after chemotherapy (arms a + b vs c + d). At a median follow-up of 72 months, A → CMF as compared to CMF significantly improved disease-free survival (DFS) with a multivariate hazard ratio (HR) = 0.740 (95% confidence interval (CI): 0.556-0.986; P = 0.040) and produced a nonsignificant improvement of overall survival (OS) (HR = 0.764; 95% CI: 0.489-1.193). The addition of GT after chemotherapy significantly improved DFS (HR = 0.74; 95% CI: 0.555-0.987; P = 0.040), with a nonsignificant improvement of OS (HR = 0.84; 95% CI: 0.54-1.32). A → CMF is superior to CMF. Adding GT after chemotherapy is beneficial for premenopausal node-positive patients.

KW - Adjuvant therapy

KW - Anthracyclines

KW - Breast cancer

KW - Chemoendocrine treatment

KW - Premenopausal

UR - http://www.scopus.com/inward/record.url?scp=20144379135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144379135&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602355

DO - 10.1038/sj.bjc.6602355

M3 - Article

VL - 92

SP - 467

EP - 474

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -